Abstract
The FDA and the National Institutes of Health (NIH) have launched a public-private partnership to advance the understanding of and accelerate the development of treatments for rare neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).The 2 federal agencies are partnering with the Critical Path Institute (C-PATH)—an independent nonprofit, public-private partnership created in 2005 under the auspices of the FDA’s Critical Path Initiative program—on the Critical Path for Rare Neurodegenerative Diseases.
NSTL
Amer Medical Assoc